School of Nursing Oncology

Chasity Washington, MPH, CHES, discusses strategies for addressing disparities in cancer care.

Five-year survival rates in renal cell carcinoma are drastically improving due to recent regulatory approvals of combination therapies involving checkpoint blockade and VEGF TKIs.

“Smarter screening” and a better understanding of the breast cancers women of color are more likely to develop are all crucial to helping these patients survive this disease at the same rates as their White counterparts.

With more oral cancer therapies available, the importance of medication adherence and education must be recognized.

Understanding the functionality and naming convention of biosimilars vs their biologic counterparts are important concepts to utilizing these agents in oncology, according to a presentation given by Teresa Knoop, MSN, RN, AOCN, during the 5th Annual School of Nursing Oncology Meeting.

Genetic testing is more important now than ever before, as biomarker-driven cancer treatments continue to receive approval across many tumor types.

In order to achieve health equity for patients with cancer, physicians must first understand the root cause of heath disparities, many of which may be invisible.

Chasity M. Washington, MPH, CHES, discusses ways to mitigate racial disparities in oncology.

Beth Sandy, MSN, CRNP, discusses the evolving treatment landscape in small cell lung cancer.